Teaching hospital sets the pace for healthcare in the Philadelphia suburbs
with unique new capabilities enabled by Masimo SET and Masimo Rainbow SET
technologies
IRVINE, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Abington Memorial
Hospital and Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and
Read-Through-Motion & Low Perfusion Pulse Oximetry, have announced the
completion of Philadelphia-based Abington Memorial Hospital's system-wide
conversion to Masimo SET Pulse Oximetry. The hospital performed an extensive
and thorough evaluation of Masimo SET technology and cited clinical preference,
patient safety and unique capabilities as key factors for the conversion.
Dr. Ara Moomjian, Chief of Neonatology at Abington Memorial Hospital, said,
"When surveyed, Abington clinicians clearly preferred Masimo SET technology
over other available pulse oximetry solutions and the superior performance of
Masimo SET during multi-departmental evaluations only served to cement the
decision."
Abington Memorial Hospital is a 570-bed regional teaching hospital in
Abington, Pennsylvania. With more than 34,000 inpatient admissions and greater
than 5,000 births annually, the hospital is a major regional referral center
for cancer care, cardiac care, and surgery (including orthopaeadic surgery and
neurosurgery) and maintains the only Level II trauma center in Montgomery
County.
By making the conversion to Masimo, Abington Memorial Hospital joins other
top hospitals in the United States -- including four of the top five -- as
listed on the US News & World Report Honor Roll, which have all adopted Masimo
SET as their primary pulse oximetry platform. Masimo SET is clinically proven
in more than 100 independent and objective studies to provide the most
trustworthy SpO2 readings even under the most difficult clinical conditions,
including patient motion and low peripheral perfusion. These studies
demonstrate that Masimo SET delivers improvements in outcomes, safety and
efficiency.
"After converting to Masimo SET, we noticed a significant decrease in
false alarms," said Dr. Stephen Snyder, Neonatologist at Abington Memorial
Hospital. "In the past, other monitors would falsely alarm in the presence of
motion or low perfusion, which would prolong the patients' length of stay.
Hospital protocols dictate that if a neonatal patient has a significant SpO2
alarm during the last 24 hours of their stay, they are required to be
monitored longer before they can be discharged."
In addition to Abington Memorial Hospital's system-wide standardization to
Masimo SET pulse oximetry, the conversion also allows hospital clinicians to
utilize Masimo Rainbow SET technology. Masimo Rainbow SET is an upgradable
noninvasive blood constituent monitoring platform that is capable of measuring
additional blood constituents that previously required invasive procedures.
Masimo Rainbow SET's first application is Pulse CO-Oximetry, the first and
only technology platform capable of continuously and noninvasively measuring
carboxyhemoglobin (SpCO) and methemoglobin (SpMet), in addition to
oxyhemoglobin (SpO2), perfusion index (PI), pleth variability index (PVI) and
pulse rate.
Joe E. Kiani, CEO of Masimo, stated, "Abington Memorial Hospital is a
large and growing teaching hospital in the Philadelphia suburbs that is
setting the pace for the next-generation of hospital physicians, specialists
and clinical staff. This conversion is especially rewarding because they have
chosen Masimo SET and Masimo Rainbow SET technologies to prepare their future
generations of healthcare professionals. We are proud that Masimo SET is the
pulse oximetry standard of care at work in Abington Memorial Hospital for
today's patients and tomorrow's healthcare leaders."
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry,
known as Masimo SET, and with it virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. Masimo
SET is clinically proven in more than 100 independent and objective studies to
provide the most trustworthy SpO2 and pulse rate measurements even under the
most difficult clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Rainbow SET continuously and noninvasively measures carboxyhemoglobin (SpCO)
and methemoglobin (SpMet), pleth variability index (PVI), in addition to
oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost
of Care by Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These
forward-looking statements are based on current expectations about future
events affecting us and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond our control, including:
risks related to our assumption that Masimo SET and Masimo Rainbow SET will
deliver a sufficient level of clinical improvement over alternative pulse
oximetry and patient monitoring systems to allow for rapid adoption of the
technology at hospitals, as well as other factors discussed in the "Risk
Factors" section of our quarterly report on Form 10-Q for the quarter ended
September 29, 2007, filed with the Securities and Exchange Commission on
November 1, 2007. Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
We do not undertake any obligation to update, amend or clarify these forward-
looking statements or the risk factors contained in our quarterly report on
Form 10-Q for the quarter ended September 29, 2007, whether as a result of new
information, future events or otherwise, except as may be required under the
federal securities laws.
Contact:
Tom McCall
Masimo Corporation
949-297-7075
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpCO, SpMet, PVI and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation.
SOURCE Masimo